Zilia Secures Bridge Financing with Linearis Ventures

Zilia Inc. has successfully closed a bridge financing round, which included participation from new investors such as Linearis Ventures, alongside reinvestment from current shareholders. This funding milestone was announced in a press release and is aimed at scaling the commercialization of Zilia's flagship technology, the Zilia Ocular™, a non-invasive device that measures biomarkers in the eye.

The Zilia Ocular™ combines imaging, spectroscopy, and artificial intelligence to provide real-time insights into ocular and systemic health. The company is advancing toward FDA clearance for its ocular oximetry technology, complementing an initial FDA 510(k) clearance received in 2023 for its Zilia Ocular FC™ retinal camera.

Linearis Ventures will also serve as a strategic advisor on AI development, leveraging its expertise to support Zilia's growth and innovation in ophthalmic biomarkers. This collaboration is part of Zilia's broader strategy to expand into cardiology and neurology, supported by a major institutional raise planned for later this year.